Cultivate Intensively for Premium Quality, Empower New Development in Pharmaceutical Industry——Pharmaceutical-grade Cellulose of Zhejiang Haishen New Materials Co., Ltd.

With the further advancement of the consistency evaluation work in China's pharmaceutical industry and the accelerated R&D of innovative preparations, the market demand for high-quality pharmaceutical-grade cellulose has been surging. Against this backdrop, relying on over 30 years of accumulated experience in cellulose R&D and production, Zhejiang Haishen New Materials gives full play to its technical advantages as a participating unit in formulating industry standards. It has targeted and overcome multiple technical difficulties in the production of pharmaceutical-grade cellulose, and successfully built a product system covering multiple categories such as hydroxypropyl methylcellulose (HPMC) and methylcellulose (MC).

The pharmaceutical-grade cellulose products of Zhejiang Haishen boast three core advantages.

First, the quality control is rigorous and precise. Compliant with the Chinese Pharmacopoeia (CP), the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP), the products are backed by a full-process quality traceability system covering raw material selection to finished product delivery. By introducing advanced testing equipment and a DCS automatic control system, the impact of human intervention on product quality is effectively eliminated. This ensures that the key indicators of each batch of products meet pharmaceutical-grade standards, with their purity and stability reaching leading levels in the industry.

Second, the technical processes are advanced and mature. Relying on the scientific research strength of its provincial-level R&D center, the enterprise has optimized and upgraded its production processes, and adopted a green and low-carbon production technology route. While improving product performance, it has achieved energy conservation and environmental protection in the production process, which is in line with the requirements of the national "dual carbon" strategy and bioeconomy development plan.

Third, the product applicability is extensive and diversified. The product series can provide customized parameter configurations such as viscosity and particle size according to the needs of different pharmaceutical preparations. It can not only meet the production requirements of ordinary oral tablets and capsules, but also adapt to the R&D and production of high-end preparations such as sustained-release preparations and controlled-release preparations, providing one-stop excipient solutions for pharmaceutical enterprises.

At present, China's pharmaceutical excipient industry is in a critical transition period from "basic guarantee" to "high-end upgrading". Relying on over 30 years of technical accumulation and rigorous quality control, Zhejiang Haishen has launched pharmaceutical-grade cellulose products that precisely meet market demands. The launch of these products will not only further enhance the enterprise's core competitiveness, but also provide strong support for the quality upgrading and import substitution of the domestic pharmaceutical excipient industry, propelling the high-quality development of China's pharmaceutical industry to a new level.

Zhejiang Haishen has established a professional sales and technical service team for its pharmaceutical-grade cellulose products, which can provide customers with full-chain services ranging from product selection and technical consultation to customized R&D, helping them improve the efficiency of preparation R&D and product quality.